News

Press Release Issued:
IASIC Opposes the Removal of Cannabis from Schedule 1

BURLINGTON, Vermont – June 25, 2024 – The International Academy on the Science and Impact of Cannabis (IASIC) released its official statement against the proposed rescheduling of Cannabis from Schedule I to Schedule III of the Controlled Substances Act:

As physicians and concerned citizens of the United States of America, the International Academy on the Science and Impact of Cannabis believes that re-scheduling will have immediate and irreparable harm to the public health and vehemently oppose the removal of cannabis from Schedule 1. Specific objections include (1) The Department of Health and Human Services (HHS) inappropriately changed the definition of currently acceptable medical use (CAMU); (2) Even under the new definition, cannabis still does not meet the requirements for CAMU; (3) Proper regulation of cannabis as a schedule 3 drug cannot be achieved while non-medical cannabis commerce is allowed.

“HHS and those who are pushing rescheduling of cannabis are unaware or ignoring the huge amount of science on the medical harms of cannabis. There is zero benefit and only problems to be had from rescheduling,” said Eric A. Voth, MD, FACP, President and Chairman of the Board, The International Academy on the Science and Impact of Cannabis.

An official request for a hearing with the DEA has been submitted by IASIC during the current open comment period, with its leadership urging the presentation of medical and scientific research from its physician-driven organization of international experts on cannabis.

IASIC has provided substantial education and background on the impending harm of the proposed rescheduling in its monthly speaker series on June 11th as well as on the High Truths on Drugs and Addiction podcast with episode #182: High Truths on Drugs and Addiction on Rescheduling of Marijuana with IASIC.

IASIC Speaker Series Presents: THC Changes in Adolescent Brain

February 16, 2023 No Comments

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Read More »

IASIC Speaker Series Presents  Cannabis and Mental Health

January 12, 2023 No Comments

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Read More »

Placebo Effect a Major Driver of Pain Reduction in Cannabis Trials

January 11, 2023 No Comments

A strong placebo response may be largely responsible for the significant pain reduction observed in clinical trials of cannabis-based therapies, results of a new meta-analysis suggest. Investigators found that while the effect size of cannabinoids on pain intensity was significant, the placebo effect was about the same. “The data from the present meta-analysis, including 1459

Read More »

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005–2019

January 9, 2023 No Comments

Since 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public

Read More »

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

January 4, 2023 No Comments

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Read More »

Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence

December 30, 2022 No Comments

Survey data suggest patients with CHS almost universally suffer from a cannabis use disorder, which has significant treatment implications. Treatment prevalence in the ED has increased substantially over a very short time period, with the highest rates seen during the Covid-19 pandemic. For more information on the International Academy on the Science and Impact of

Read More »

Legalizing psychedelics does more harm than good

December 26, 2022 No Comments

Citizens of Colorado will be voting on Proposition 122, which would allow decriminalization, distribution and access to psychedelics. It will also allow possession, personal use and growing, as well as uncompensated gifting. Is this going to be good for Colorado and personal health? There is emerging data that components of psychedelics may have medicinal value

Read More »

First Medical Textbook on Cannabis in Medicine

Listen to podcast High Truths on Drugs and Addiction on your favorite platform. ​Hightruth.com

Most Recent News

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Read More »

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Read More »

IASIC Speaker Series Presents: Case Report on Cannabis-Induced Acute Encephalopathy in Elderly After Taking CBD

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Read More »
Scroll to Top